Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matthew S Block

Showing results (71-80 of 117) with videos related to

Pageof 12
Sort By:
European Journal of Cancer (Oxford, England : 1990)|March 11, 2015
PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samplesBoris Winterhoff, Luisa Freyer, Edward Hammond, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 14, 2016
A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndromeAminah Jatoi, Megan E Grudem, Travis J Dockter, et al.
Mayo Clinic Proceedings|February 1, 2016
Recurrence and Survival Outcomes After Percutaneous Thermal Ablation of Oligometastatic MelanomaMariah L White, Thomas D Atwell, A Nicholas Kurup, et al.
Annals of Surgical Oncology|May 30, 2026
Accuracy of Index Lymph Node Pathology in Predicting Overall Response to Neoadjuvant Immunotherapy for Clinical Stage III Melanoma: Results From the Prospective NeoACTIVATE Arm C (NCT03554083) SubstudyTina J Hieken, Thomas J Flotte, David Zahrieh, et al.
Annals of Surgical Oncology|June 17, 2026
ASO Visual Abstract: Accuracy of Index Lymph Node Pathology in Predicting Overall Response to Neoadjuvant Immunotherapy for Clinical Stage III Melanoma-Results from the Prospective NeoACTIVATE Arm C (NCT03554083) SubstudyTina J Hieken, Thomas J Flotte, David Zahrieh, et al.
British Journal of Cancer|June 3, 2016
Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancerChen Wang, Boris J Winterhoff, Kimberly R Kalli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2018
Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer PatientsKimberly R Kalli, Matthew S Block, Pashtoon M Kasi, et al.
JCI Insight|May 17, 2016
T cell Bim levels reflect responses to anti-PD-1 cancer therapyRoxana S Dronca, Xin Liu, Susan M Harrington, et al.
Journal for Immunotherapy of Cancer|November 2, 2023
Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockadeYan Luo, Barath Shreeder, James W Jenkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2019
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1Neeta Somaiah, Matthew S Block, Joseph W Kim, et al.
Pageof 12

Showing results (71-80 of 117) with videos related to

Sort By:
Pageof 12
European Journal of Cancer (Oxford, England : 1990)|March 11, 2015
PG545 enhances anti-cancer activity of chemotherapy in ovarian models and increases surrogate biomarkers such as VEGF in preclinical and clinical plasma samplesBoris Winterhoff, Luisa Freyer, Edward Hammond, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|November 14, 2016
A proof-of-concept trial of protein kinase C iota inhibition with auranofin for the paclitaxel-induced acute pain syndromeAminah Jatoi, Megan E Grudem, Travis J Dockter, et al.
Mayo Clinic Proceedings|February 1, 2016
Recurrence and Survival Outcomes After Percutaneous Thermal Ablation of Oligometastatic MelanomaMariah L White, Thomas D Atwell, A Nicholas Kurup, et al.
Annals of Surgical Oncology|May 30, 2026
Accuracy of Index Lymph Node Pathology in Predicting Overall Response to Neoadjuvant Immunotherapy for Clinical Stage III Melanoma: Results From the Prospective NeoACTIVATE Arm C (NCT03554083) SubstudyTina J Hieken, Thomas J Flotte, David Zahrieh, et al.
Annals of Surgical Oncology|June 17, 2026
ASO Visual Abstract: Accuracy of Index Lymph Node Pathology in Predicting Overall Response to Neoadjuvant Immunotherapy for Clinical Stage III Melanoma-Results from the Prospective NeoACTIVATE Arm C (NCT03554083) SubstudyTina J Hieken, Thomas J Flotte, David Zahrieh, et al.
British Journal of Cancer|June 3, 2016
Expression signature distinguishing two tumour transcriptome classes associated with progression-free survival among rare histological types of epithelial ovarian cancerChen Wang, Boris J Winterhoff, Kimberly R Kalli, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 17, 2018
Folate Receptor Alpha Peptide Vaccine Generates Immunity in Breast and Ovarian Cancer PatientsKimberly R Kalli, Matthew S Block, Pashtoon M Kasi, et al.
JCI Insight|May 17, 2016
T cell Bim levels reflect responses to anti-PD-1 cancer therapyRoxana S Dronca, Xin Liu, Susan M Harrington, et al.
Journal for Immunotherapy of Cancer|November 2, 2023
Th17-inducing dendritic cell vaccines stimulate effective CD4 T cell-dependent antitumor immunity in ovarian cancer that overcomes resistance to immune checkpoint blockadeYan Luo, Barath Shreeder, James W Jenkins, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 23, 2019
First-in-Class, First-in-Human Study Evaluating LV305, a Dendritic-Cell Tropic Lentiviral Vector, in Sarcoma and Other Solid Tumors Expressing NY-ESO-1Neeta Somaiah, Matthew S Block, Joseph W Kim, et al.
Pageof 12